{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:40:03Z","timestamp":1773193203279,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clgc.2019.03.023","type":"journal-article","created":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T00:12:29Z","timestamp":1554509549000},"page":"254-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Niels","family":"Fristrup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.03.023_bib1","first-page":"507","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2019.03.023_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.6004\/jnccn.2015.0022","article-title":"Kidney cancer, version 3.2015","volume":"13","author":"Motzer","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2019.03.023_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ejca.2013.10.010","article-title":"Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2","volume":"50","author":"Soerensen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.03.023_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab vs. everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.023_bib5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab vs. sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.023_bib6","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New insights into molecular mechanisms of sunitinib-associated side effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2019.03.023_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mdv612","article-title":"Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)","volume":"27","author":"Motzer","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.03.023_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib vs. sunitinib in metastatic renal cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.023_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/annonc\/mdv595","article-title":"Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy","volume":"27","author":"Rugo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.03.023_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/tcrm.2006.2.2.159","article-title":"Oral mucositis induced by anticancer treatments: physiopathology and treatments","volume":"2","author":"Lionel","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clgc.2019.03.023_bib11","doi-asserted-by":"crossref","first-page":"5035217","DOI":"10.1155\/2018\/5035217","article-title":"Stomatitis and VEGFR-tyrosine kinase inhibitors (VR-TKIs): a review of current literature in 4369 patients","volume":"2018","author":"Arena","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clgc.2019.03.023_bib12","first-page":"1271","article-title":"Null association between prostate cancer and serum folate, vitamin B (6), vitamin B (12), and homocysteine","volume":"12","author":"Weinstein","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clgc.2019.03.023_bib13","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.023_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.023_bib15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib vs. sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.023_bib16","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.03.023_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.03.023_bib18","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib vs. everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.023_bib19","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.03.023_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/0284186X.2018.1433324","article-title":"A\u00a0randomized phase II trial of interleukin-2 and interferon-alpha plus bevacizumab vs. interleukin-2 and interferon-alpha in metastatic renal cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1","volume":"57","author":"Donskov","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2019.03.023_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","article-title":"Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review","volume":"17","author":"Boers-Doets","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2019.03.023_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.adaj.2017.10.024","article-title":"Stomatitis associated with mammalian target of rapamycin inhibition: a review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer","volume":"149","author":"Chambers","year":"2018","journal-title":"J\u00a0Am Dent Assoc"},{"issue":"5 suppl 61","key":"10.1016\/j.clgc.2019.03.023_bib23","first-page":"S102","article-title":"Folate supplementation during methotrexate therapy for rheumatoid arthritis","volume":"28","author":"Morgan","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clgc.2019.03.023_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2019.03.023_bib25","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients","volume":"113","author":"Donskov","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.03.023_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/0284186X.2015.1091499","article-title":"A\u00a0five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: results from DARENCA study 2","volume":"55","author":"Soerensen","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2019.03.023_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bju.12940","article-title":"Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma","volume":"117","author":"Rautiola","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.03.023_bib28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.03.023_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2017.05.004","article-title":"Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma","volume":"81","author":"Penttila","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318306888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318306888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:54Z","timestamp":1761564714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318306888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1558767318306888"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.03.023","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}